Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 12/30/2025

Duration and Management of Ticagrelor Therapy After Drug‑Eluting Stent Placement

Standard Duration Based on Clinical Presentation

  • Acute Coronary Syndrome (ACS) – The American College of Cardiology (ACC) recommends that ticagrelor 90 mg twice daily be continued for at least 12 months after drug‑eluting stent (DES) implantation, irrespective of stent type. 1
  • ACS – Ticagrelor is preferred over clopidogrel for maintenance antiplatelet therapy in this setting. 2
  • ACS – Low‑dose aspirin (81 mg daily, acceptable range 75–100 mg) should be taken concurrently with ticagrelor. 1
  • Stable Ischemic Heart Disease (SIHD) – The ACC advises a minimum of 6 months of ticagrelor after DES implantation. 2
  • SIHD – When bleeding risk is low, a 6‑month duration is standard; shorter courses (1–6 months) may be considered for patients at higher bleeding risk. [3][4]
  • SIHD – Aspirin 81 mg daily should be maintained indefinitely after DES placement. 2

Extension Beyond Standard Duration

  • Criteria for extending ticagrelor beyond 12 months (ACS) – Extension is reasonable only if the patient (a) tolerated dual antiplatelet therapy (DAPT) without any bleeding during the first 12 months, (b) is not at high bleeding risk, and (c) has had no overt bleeding events. [1][4]

  • High‑risk coronary anatomy favoring extension – Multivessel disease, including left‑main involvement, supports prolonged DAPT. 2
  • High‑risk comorbidity favoring extension – Chronic kidney disease is an additional factor that may justify extended therapy. 5

Early Discontinuation Scenarios

  • ACS patients with high bleeding risk – Discontinuation after 6 months may be appropriate if the patient (a) requires oral anticoagulation, (b) faces a major intracranial surgery, or (c) experiences significant overt bleeding. [4][2]

  • SIHD patients with high bleeding risk – Discontinuation after 3 months may be reasonable under similar circumstances (need for oral anticoagulation, high surgical bleeding risk, or overt bleeding). [4][2]

  • General principle – If the anticipated morbidity from bleeding clearly outweighs the expected ischemic benefit, earlier cessation of ticagrelor is justified. [1][2]6

Aspirin Co‑therapy

  • Dose recommendation – Low‑dose aspirin 81 mg daily (range 75–100 mg) should be used together with ticagrelor. [1][5]
  • Bleeding risk – Aspirin doses >100 mg increase bleeding without improving antithrombotic efficacy. 5
  • Post‑ticagrelor – Aspirin monotherapy should be continued for life after stopping ticagrelor. 5

Peri‑operative Management (CABG)

  • Pre‑operative pause – Ticagrelor should be stopped at least 3 days before an elective coronary artery bypass graft (CABG). 3
  • Post‑operative resumption – In ACS patients, ticagrelor should be restarted as soon as feasible after CABG to complete the intended 12‑month course. 1
  • Aspirin continuity – Aspirin should be maintained throughout the peri‑operative period. 3

Contra‑indications and Common Pitfalls

  • Premature discontinuation in ACS – Stopping ticagrelor before 12 months without a compelling bleeding indication markedly raises the risk of stent thrombosis. 1
  • Aspirin dose limit – Do not use aspirin doses >100 mg daily when combined with ticagrelor, as this heightens bleeding risk. 5
  • Prasugrel avoidance – Prasugrel should not be prescribed instead of ticagrelor in patients with a prior stroke or transient ischemic attack. [1][6]

Ticagrelor Therapy Duration After Drug-Eluting Stent Placement

Duration Based on Clinical Presentation

  • The American College of Cardiology recommends that ticagrelor should be given for at least 12 months if placed for acute coronary syndrome (ACS), and for at least 6 months if placed for stable ischemic heart disease (SIHD) 7, 8, 9
  • For ACS patients, ticagrelor 90 mg twice daily should be given for at least 12 months after DES implantation, and ticagrelor is preferred over clopidogrel for maintenance P2Y12 inhibitor therapy 7, 8, 9
  • Daily aspirin dose of 81 mg (range 75-100 mg) should be continued indefinitely for ACS and SIHD patients 7, 8
  • For patients who have tolerated DAPT without bleeding complications and are not at high bleeding risk, continuation of ticagrelor beyond 12 months may be reasonable 8, 9

Special Considerations for Early Discontinuation

  • In ACS patients with DES who develop high bleeding risk, discontinuation of ticagrelor after 6 months may be reasonable 7, 8, 10
  • In SIHD patients with DES who develop high bleeding risk, discontinuation of P2Y12 inhibitor therapy after 3 months may be reasonable 7, 10
  • If the risk of morbidity from bleeding outweighs the anticipated benefit of the recommended duration, earlier discontinuation of P2Y12 inhibitor therapy is reasonable 11, 12

Important Counseling Points

  • Patients should be counseled on the importance of compliance with antiplatelet therapy, and therapy should not be discontinued before discussion with their cardiologist 13

Common Pitfalls and Caveats

  • Prasugrel should not be administered to patients with a prior history of stroke or TIA 7, 8
  • Proton pump inhibitors should be used in patients with a history of gastrointestinal bleeding who require DAPT, but routine use is not recommended for patients at low risk of gastrointestinal bleeding 11

REFERENCES